🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#VisualAbstract de Annual Dialysis Conference, sugerencia de Rolando Claure, MD, FASN, FISN 🇧🇴. Los 5 tipo de síndrome cardiorenal. Almudena Castro Conde Alfonso Valle Jose Luis Górriz Chuletas Médicas Residentes semFYC + S JovSEN S.E.N. Nefrología SVCardio SVHTA SEMERGEN | Médicos de AP #YoPrefieroMFyC Sociedad Madrileña de Nefrología (SOMANE)

Finalizó nuestro XLII Congreso de las Enfermedades Cardiovasculares de la SVCardio #svc25 Muchas gracias a todos los ponentes, patrocinadores, y por supuesto a todos los asistentes ❗️ Nos vemos en #svc26❗️

Clinical staging to guide management of metabolic disorders and their sequelae: #EAS What is Systemic Metabolic Disorder? It’s not just #obesity. It’s a multi-organ metabolic disease driven by adiposity, insulin resistance, inflammation & lipotoxicity. #MetabolicHealth

🔴 Tirzepatide as Compared with Semaglutide for the Treatment of Obesity A head-to-head trial finally answers: is tirzepatide more effective than semaglutide for obesity in non-diabetics? We@NEJM: the SURMOUNT-5 trial. #Obesity #CardioTwitter #GLP1 #Tirzepatide #Semaglutide

Lunes de vídeo! En 5 minutos el gran experto doctor Alfonso Valle nos cuenta todo lo que tenemos que saber sobre riesgo residual en enfermedad CV 📹🔝No te lo pierdas!! youtu.be/kM3s79E07vA?si… Diana Domingo Valero HospitalLaFe Raquel López Vilella Soc Esp Cardiología Luis Almenar Bonet Julia Martínez Solé

#VICTORIA demonstrated benefits of sGC stimulator vericiguat in recent worsening HF & led to its #FDA approval in '21 New JACC Journals nationwide analysis finds use thus far has been limited jacc.org/doi/abs/10.101… Will #VICTOR (no recent worsening HF) support its broader use?

🔴Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial #HeartFailure2025 💡 The FINEARTS-HF trial shows that finerenone significantly ⬇️NT-proBNP and clinical events in patients with

✳️ Beneficios del uso continuado de SZC en pacientes con disfunción sistólica y potasio elevado ⚕️ Alfonso Valle Muñoz Alfonso Valle 👀 cardioteca.com/blog-ciclosili…

🔥#LBCT #VELOCITY_study examined a simplified #vericiguat dose titration pathway for #HFrEF >9 of 10 pts safely tolerated a 5 mg starting dose (bypassing traditional 2.5 mg step) #SimPub European Society of Cardiology Journals #EJHF EJHF Editor-in-Chief #HeartFailure2025 Duke Clinical Research Institute 🔗onlinelibrary.wiley.com/doi/10.1002/ej…

Finerenone reduced the risk of new-onset atrial fibrillation by 17% in high-risk patients with CKD, T2D, or HF. A reminder that prevention isn’t just possible—it’s powerful. Alfonso Valle #AFib #CardioRenal #PreventionMatters

🧵 Can a diabetes drug reverse hypertrophic cardiomyopathy? A rigorous new study says yes—empagliflozin rewires heart metabolism and improves function in a mouse model of HCM. #CardioTwitter #HeartFailure #Metabolism #SGLT2i 🧬🫀👇 💡 Background: HCM is driven by sarcomeric

🌟5 min de Oro en Salud CV🌟 🎥 En el vídeo de hoy, la Dra Diana Domingo Valero nos hace una excelente actualización de avances en la dislipemia: terapias subcutáneas ¡Si no lo habéis visto aún, no os lo perdáis! 🔗 Aquí os dejamos el enlace. youtu.be/prgo0Xkpmhk?si…

Gracias a la Dra Patricia Palau Patrícia Palau por su excelente sesión sobre la utilidad de la ergoespirometria para el estudio de la disnea #latido El 19 de junio última sesión del curso. Toda la info en @svcardio y Organon España svcardio.org/latido-2-0

.@juliasellerm: “El FRESH-UP cuestiona la restricción hídrica sistemática en pacientes con IC ambulatoria en fase estable y nos sugiere que un enfoque más liberal puede mejorar la calidad de vida sin un aumento de eventos adversos". #BlogSEC JóvenesSEC ow.ly/N7CB50W1mw8

Top3 heart failure trials in May 2025 🥇Finerenone in HF with improved EF JAMA 🥈Albuminuria as a diagnostic criterion and a therapeutic target in HF European Society of Cardiology Journals 🥉HF and obesity European Society of Cardiology Journals

🔴An Observational Study of Cardiovascular Outcomes of Tirzepatide vs GLP-1 Receptor Agonists 🚨New Real-World Evidence: Tirzepatide vs GLP-1 RAs for CV Outcomes in T2D A large observational study compares CV risk in patients treated with tirzepatide vs GLP-1 receptor agonists.

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes 🔗 nejm.org/doi/full/10.10… 🧵1NEW in NEJM: Combining #Finerenone + #Empagliflozin significantly reduced albuminuria in patients with #CKD & #T2D. The CONFIDENCE trial offers a new strategy in tackling

Hoy hemos puesto el broche final al programa de doctorado Universitat València con la consecución del premio extraordinario. Nada de esto habría sido posible sin el apoyo y la excelencia de mis tutores Julio y Patrícia Palau Mi mayor agradecimiento y cariño!

The American Heart Association just published their alcohol recommendations today which line up with the report by the National Academies. Moderate EtOH intake, up to 7 drinks per week (1/day), is without risk (and may be beneficial for cardiovascular outcomes) American Heart Association

How obesity, inflammation & systems cardiology are reshaping our role as cardiovascular clinicians. 🔬❤️ Based on @eurheartj article by Prof. Thomas Lüscher 👇 1/ Modern cardiology evolved into hyper-specialization: But what about our generalist roots? The rise of complex